指南与共识消化、代谢与肾脏急症心脑血管急症重症综合管理与镇静镇痛

专家小组建议:慢性肾脏病和心力衰竭患者高钾血症的识别与管理及帕替罗姆的作用

Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure.
指南 / 共识 · J Manag Care Spec Pharm · 2017-01-01
一句话结论专家小组提出急性/慢性照护中高钾血症诊断流程,并认为帕替罗姆是合并慢性肾脏病和/或心力衰竭患者高钾血症的可行选择。

7名独立专家(3名肾脏科、2名心脏科、2名急诊科医生)召开虚拟小组会议,讨论合并心力衰竭和慢性肾脏病的高钾血症治疗现状、挑战、经济影响和照护差距。小组指出高钾血症可导致危及生命的并发症,但治疗范式约50年无重大进展,直到帕替罗姆获批。小组制定了「急性照护/慢性照护中高钾血症治疗拟议诊断流程」。小组同意帕替罗姆似乎是慢性肾脏病和/或心力衰竭患者及慢性高钾血症患者管理的可行选择。

要点

  • 小组由7名独立专家组成(3名肾脏科、2名心脏科、2名急诊科医生),旨在为合并心力衰竭和慢性肾脏病的高钾血症患者制定实用解决方案。
  • 小组指出高钾血症是严重疾病,可导致危及生命的并发症,但治疗范式约50年无重大进展,直到帕替罗姆获批。
  • 小组制定了「急性照护/慢性照护中高钾血症治疗拟议诊断流程」。
  • 小组同意帕替罗姆似乎是慢性肾脏病和/或心力衰竭患者及慢性高钾血症患者管理的可行选择。
  • 小组指出该患者群体管理仍存在缺乏统一治疗指南和共识等问题。

适用人群与场景

  • 合并心力衰竭和慢性肾脏病的高钾血症患者。
  • 慢性高钾血症患者。

处置流程与药物剂量

  • 小组制定了「急性照护/慢性照护中高钾血症治疗拟议诊断流程」。
  • 小组同意帕替罗姆似乎是慢性肾脏病和/或心力衰竭患者及慢性高钾血症患者管理的可行选择。

红旗征与不能漏的情况

  • 高钾血症是严重疾病,可导致危及生命的并发症。

研究设计与关键结果

  • 7名独立专家(3名肾脏科、2名心脏科、2名急诊科医生)召开虚拟小组会议,讨论合并心力衰竭和慢性肾脏病的高钾血症治疗现状、挑战、经济影响和照护差距。
  • 小组指出高钾血症治疗范式约50年无重大进展,直到帕替罗姆获批。
  • 小组制定了「急性照护/慢性照护中高钾血症治疗拟议诊断流程」。
  • 小组同意帕替罗姆似乎是慢性肾脏病和/或心力衰竭患者及慢性高钾血症患者管理的可行选择。

证据类型、等级与局限

  • 证据类型:专家小组建议。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 小组指出该患者群体管理仍存在缺乏统一治疗指南和共识的问题。
  • 小组同意帕替罗姆似乎是慢性肾脏病和/或心力衰竭患者及慢性高钾血症患者管理的可行选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Virtual panel meetings were conducted among 7 physicians, all of whom are independent experts, including 3 nephrologists, 2 cardiologists, and 2 emergency medicine physicians (the panel). The panel met with the purpose of discussing the current treatment landscape, treatment challenges, economic impact, and gaps in care for patients with hyperkalemia that is associated with heart failure and chronic kidney disease. The stated goal of the panel discussion was to develop practical solutions in the identification and management of hyperkalemia in this patient population. The panel noted that hyperkalemia is a serious condition that can lead to life-threatening complications, yet the treatment paradigm for hyperkalemia has remained without major advances for approximately 50 years, until the approval of patiromer. A number of issues still exist in the management of this patient population, including the lack of uniform treatment guidelines and consensus regarding the approach to treatment. As part of its effort, the panel developed an algorithm, the Proposed Diagnostic Algorithm for Hyperkalemia Treatment in the Acute Care Setting/Chronic Care. The panel agreed that patiromer appears to be a viable option for the management of hyperkalemia in patients with chronic kidney disease and/or heart failure and in patients who experience chronic hyperkalemia.

DISCLOSURES: This panel discussion was funded by Relypsa and facilitated by Magellan Rx Management. Rafique is a principal investigator for Relypsa and serves as a consultant for Instrumentation Laboratory, Magellan Health, Relypsa, and ZS-Pharma. Butler serves as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CardioCell, Janssen, Merck, Novartis, Relypsa, and ZS-Pharma. Lopes and Farnum are employed by Magellan Rx Management. Rafique designed the management protocol for this panel discussion and contributed to the writing and editing of this report document. The other authors report no conflicting interests. Relypsa is the manufacturer of Veltassa (patiromer).

来源:J Manag Care Spec Pharm,查看原文。版权归原作者所有。

参考来源

  1. Rafique Z, Weir MR, Onuigbo M, et al. Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. J Manag Care Spec Pharm. 2017. PMID: 28485203. doi:10.18553/jmcp.2017.23.4-a.s10

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。